Our decision to selectively partner our proprietary technology has validated our investment in suprachoroidal delivery using our SCS Microinjector® and has expanded our overall development pipeline.

REGENXBIO has exclusive worldwide rights to our SCS Microinjector for delivery of adeno-associated virus (AAV)-based gene therapy to the suprachoroidal space (SCS®) to treat wet AMD, diabetic retinopathy and certain other conditions for which anti-VEGF treatment is the standard of care.

Aura Biosciences has a worldwide licensing agreement for the use of our SCS Microinjector to deliver their proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers, including choroidal melanoma.

BioCryst Pharmaceuticals has an exclusive, worldwide license to use our SCS Microinjector for the delivery of their proprietary plasma kallikrein inhibitor, avoralstat, for the treatment and prevention of diabetic macular edema.

We have completed licensing agreements with ideal partners for the commercialization and further development of XIPERE.

Bausch + Lomb, a leading global eye health company dedicated to helping people see better to live better, has the exclusive license for the commercialization and development of XIPERE in the United States and Canada.

Arctic Vision, a specialty ophthalmology company based in China, has the exclusive license for the commercialization and development of XIPERE in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries.

To learn more about our programs and potential business development opportunities, please contact

Rick McElheny, VP, Corporate Development at